You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
綠葉製藥(02186)旗下腫瘤線產品LY01008完成中國三期臨床主要療效指標觀察
阿思達克 11-04 12:26

綠葉製藥(02186.HK)公布,腫瘤線產品LY01008(Avastin之生物類似藥)於今年5月在中國完成一項與Avastin療效和安全性對比的III期臨床試驗的入組,共計入組648例患者,目前在盲態下已完成主要療效指標客觀緩解率(ORR)的觀察。

該公司指,LY01008為適用於非小細胞肺癌或結腸直腸癌的重組抗VEGF人源化單克隆抗體注射液,而據IQVIA數據,市場上的可比產品Avastin去年的全球銷售額為68.49億瑞士法郎,當中內地銷售額為17.4億元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account